Cantargia obtains “Intention to Grant” notice from the European Patent Office

Cantargia AB (“Cantargia”) today announced that the European Patent Office (EPO) issued an “Intention to Grant” notice for Cantargia’s patent application concerning IL1RAP as a target molecule for antibody therapy and diagnostic methods of leukemia.

Cantargia has received the information that the company obtained an “Intention to Grant” notice from EPO regarding the patent application EP2467403 which concerns IL1RAP as a target molecule for antibody therapy as well as diagnostic methods of leukemia. In summary, “Intention to Grant” means that the EPO likely will grant the patent application. Before the final decision can be obtained, further actions must be taken by both parties before a patent can be granted.

Göran Forsberg, CEO, comments

-”We are very pleased about this progress. It is an important step forward in the further reinforcement of a strong and robust patent portfolio for Cantargia’s product candidate CAN04.”

Certified Adviser
Sedermera Fondkommission is Cantargia’s Certified Adviser.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

About Us

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company which is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

Subscribe

Documents & Links